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ABSTRACT
Introduction Rapid, robust and continually updated 
evidence synthesis is required to inform management of 
COVID-19 in pregnant and postpartum women and to keep 
pace with the emerging evidence during the pandemic.
Methods and analysis We plan to undertake a living 
systematic review to assess the prevalence, clinical 
manifestations, risk factors, rates of maternal and perinatal 
complications, potential for mother- to- child transmission, 
accuracy of diagnostic tests and effectiveness of treatment 
for COVID-19 in pregnant and postpartum women 
(including after miscarriage or abortion). We will search 
Medline, Embase, WHO COVID-19 database, preprint 
servers, the China National Knowledge Infrastructure 
system and Wanfang databases from 1 December 2019. 
We will supplement our search with studies mapped by 
Cochrane Fertility and Gynaecology group, Evidence for 
Policy and Practice Information and Co- ordinating Centre 
(EPPI- Centre), COVID-19 study repositories, reference 
lists and social media blogs. The search will be updated 
every week and not be restricted by language. We will 
include observational cohort (≥10 participants) and 
randomised studies reporting on prevalence of COVID-19 
in pregnant and postpartum women, the rates of clinical 
manifestations and outcomes, risk factors in pregnant 
and postpartum women alone or in comparison with 
non- pregnant women with COVID-19 or pregnant women 
without COVID-19 and studies on tests and treatments 
for COVID-19. We will additionally include case reports 
and series with evidence on mother- to- child transmission 
of SARS- CoV-2 in utero, intrapartum or postpartum. We 
will appraise the quality of the included studies using 
appropriate tools to assess the risk of bias. At least two 
independent reviewers will undertake study selection, 
quality assessment and data extraction every 2 weeks. 
We will synthesise the findings using quantitative random 
effects meta- analysis and report OR or proportions 
with 95% CIs and prediction intervals. Case reports and 
series will be reported as qualitative narrative synthesis. 
Heterogeneity will be reported as I2 and τ2 statistics.
Strengths and limitations of this study
 ► Our living systematic review will be underpinned by 
a comprehensive literature search, study quality as-
sessment and appropriate planned meta- analysis to 
efficiently collate the overall findings on COVID-19 in 
pregnant and postpartum women.
 ► We will continuously update our search, study se-
lection, data extraction, analysis and reporting of the 
findings at prespecified time intervals.
 ► Rapid publication of new studies with new outcomes 
of interest, screening and testing strategies and re-
porting of novel treatments may require changes 
in the review protocol, specifically regarding data 
extraction and search strategies for future updates.
 ► This review may be subjected to publication bias, 
since studies with perceived positive results may be 
published faster than those with perceived negative 
results, thus we will continuously review registries of 
randomised controlled trials to detect trials that should 
have reported results, but that have not done so and 
will contact corresponding authors to obtain results.
 ► The dynamic nature of the living systematic review 
requires dedicated team of committed researchers 
and resources, efficient peer review and support of the 
journal editors, to ensure that findings are rapidly pub-
lished in the public domain with provision for contin-
uous updates to inform living guidelines and policies.
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Ethics and dissemination Ethical approval is not required as this is a 
synthesis of primary data. Regular updates of the results will be published 
on a dedicated website (https://www. birmingham. ac. uk/ research/ who- 
collaborating- centre/ pregcov/ index. aspx) and disseminated through 
publications, social media and webinars.
PROSPERO registration number CRD42020178076.
INTRODUCTION
Coronavirus disease caused by the SARS- CoV-2 was 
declared a pandemic by the WHO on 11 May 2020.1 In 
the first 3 months of the pandemic alone, over 4.5 million 
individuals have been affected—the infection continues 
to spread rapidly.2 Case fatality rates range from 0.4% to 
3.6% depending on the country and detection method.3 4 
In previous serious coronavirus outbreaks caused by SARS 
and middle east respiratory syndrome, the rates of inten-
sive care unit admission and mortality were significantly 
higher in infected pregnant than non- pregnant women, 
and adverse pregnancy outcomes were common.5 There 
are concerns about the potential effects of SARS- CoV-2 
infection on mothers and babies, including the risks of 
transmission to the fetus and neonate.6 Some countries 
such as the UK have classed pregnant women as a vulner-
able group requiring shielding during the pandemic.7 
Black and ethnic minority individuals are considered to 
be more likely to be infected and have severe COVID-19 
disease than Caucasian individuals.8–10
There has been a rapid increase in the numbers of 
published studies and reports on the prevalence of 
SARS- CoV-2 infection in pregnancy, risk factors, mother- 
to- child transmission, effects on pregnant and recently 
pregnant women, including those who have delivered 
or had a recent abortion, and their babies.11 Traditional 
systematic reviews are not able to keep pace with the rapid 
pace of publications and quickly become outdated.12 
Furthermore, numerous systematic reviews, addressing 
similar questions and including identical numbers of 
studies that differ very slightly from each other, make it 
challenging for guideline makers to identify the up- to- 
date evidence.13 14 Many of these reviews do not follow 
reporting guidelines and other general principles of 
conducting robust systematic reviews, often including 
case series and case–control studies in the meta- analysis 
resulting in biassed estimates.
Any recommendation on the care of pregnant 
women and recently pregnant women with suspected 
or confirmed COVID-19, and their babies, should be 
based on robust evidence. Clinicians need a single point 
of reference that comprehensively provides up- to- date 
evidence for key questions. In a rapidly changing research 
and clinical environment, this requires a clear prospec-
tive plan to update the available evidence beyond conven-
tional systematic reviews and meta- analyses. We propose 
to undertake a living systematic review to address the key 
research questions on SARS- CoV-2 infection in pregnant 
and postpartum women, including after childbirth and 
early pregnancy loss.
Aim
Our goal is to provide up- to date evidence on the risks and 
risk factors for COVID-19 and associated complications 
in pregnant and postpartum women and their babies 
through a living systematic review and meta- analysis and 
to assess the accuracy of diagnostic tests and effectiveness 
of treatment in the management of the disease.
Objectives
In pregnant and postpartum women (including after 
miscarriage or abortion):
 ► To determine the prevalence of and risk factors for 
SARS- CoV-2 infection and severe COVID-19.
 ► To evaluate the accuracy of tests and prediction 
models for screening, diagnosis and prediction of 
COVID-19 and its complications.
 ► To assess the effects of interventions for prevention of 
SARS- CoV-2 infection.
In pregnant and postpartum women (including after 
miscarriage) with suspected or confirmed COVID-19:
 ► To study the rates of clinical symptoms and signs, labo-
ratory and radiological manifestations of the disease 
and compare against non- pregnant women.
 ► To assess the rates and risk factors for COVID- related 
and pregnancy- related maternal and perinatal 
outcomes and compare against non- pregnant women 
with COVID-19 and pregnant women without the 
disease, respectively.
 ► To determine the risks and risk factors for mother–
child transmission of SARS- CoV-2 in utero, intra and 
peripartum, the prevalence and persistence of the 
viral particles or immunological response in breast 
milk, amniotic fluid, cord blood, placenta, vaginal 
fluids and faeces in women and their babies (naso-
pharyngeal/throat swabs, blood, saliva, faeces).
 ► To assess the effects of interventions to prevent 
COVID- related complications.
 ► To determine whether the rates of prevalence, clin-
ical manifestations, outcomes and risk factors vary by: 
(a) screening and testing strategy for SARS- CoV-2, 
(b) selection of populations, (c) risk status of the 
included women, timing of exposure (first, second, 
third trimester, postpartum), World Bank economic 
region (low, middle and high income) and quality of 
studies (low, high).
METHODS
Our systematic review protocol is registered in Prospero.15 
We will regularly repeat the searches, data extraction and 
analyses as described in figure 1.
Literature search
We will carry out a systematic search on the WHO Data-
base of publications on COVID-19, the Evidence for Policy 
and Practice Information and Co- ordinating Centre 
(EPPI- Centre) map of the current evidence on COVID-
19, Cochrane databases, China National Knowledge 
Infrastructure, Wanfang and preprint databases (ArXiv, 
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BiorXiv, medRxiv, search.bioPreprint), the reference lists 
of included studies, relevant systematic reviews and guide-
lines published by national and international professional 
societies, COVID-19 research websites16 17 and follow 
blogs dedicated to the identification of primary case 
reports, case series, observational studies or randomised 
controlled trials (RCT) describing women affected by 
COVID-19 in pregnancy. We will also link with established 
groups conducting surveillance and research studies in 
pregnant women with COVID-19 to access their aggre-
gate study data.18–20 There will be no language restric-
tions. The search findings will be exported to Covidence 
(http:// covidence. org/), an online programme that 
facilitates study selection and screening, recommended 
by the Cochrane Collaboration.21 Our search will be 
updated weekly, and we shall review this frequency every 
2 months. The search syntax for the Pubmed database is 
provided in online supplemental appendix 1
Study selection, quality assessment and data extraction
Study selection will be a two- stage process: titles and/
or abstracts of studies will be screened first, followed 
by evaluation of full texts for eligibility by two indepen-
dent reviewers. Disagreements will be resolved through 
discussion or by consulting a third reviewer. We will 
include all cohort studies (with at least 10 participants) 
and randomised trials reporting on clinical outcomes 
relating to SARS- CoV-2 infection involving pregnant and 
postpartum (which includes postmiscarriage/abortion 
period) women and their babies. We defined cohort 
studies as those that included women based on exposure, 
followed- up over specified time and reported outcomes.22 
Case reports and case series will only be included to 
answer the research questions relating to mother- to- child 
transmission.
We will look for serological (IgM) and/or reverse tran-
scriptase PCR (RT- PCR) confirmation of infection in 
amniotic fluid, placenta, cord, newborn and maternal 
blood and newborn and maternal respiratory secre-
tions (at birth, 24 and >48 hours after birth) to distin-
guish between congenital, intrapartum and postpartum 
transmission. Women with a respiratory sample (naso/
oropharyngeal swab or tracheal/bronchoalveolar lavage) 
positive for SARS- CoV-2 RT- PCR or positive SARS- CoV-2 
serological tests will be considered to have confirmed 
COVID-19. We will also assess risk factors such as mode 
of delivery, maternal disease severity, gestational age of 
maternal infection, preterm delivery, rooming- in and 
breast feeding on mother- to- child transmission. Women 
with a clinical diagnosis based on chest CT or radiograph 
or other features will be considered as suspected COVID-
19. Table 1 provides the details of risk factors, maternal 
and perinatal outcomes that will be evaluated in the 
review.
We will assess the risk of bias for included cohort 
studies using the Newcastle Ottawa Scale for comparative 
cohorts,23 the Cochrane Risk of Bias 2 tool for randomised 
trials,24 Quality Assessment of Diagnostic Accuracy Studies 
2 (QUADAS-2) for diagnostic accuracy studies25 and the 
tool outlined by Hoy et al26 for prevalence studies. A prepi-
loted form will be used for data extraction of the included 
studies. Two reviewers will independently extract data 
and disagreements will be resolved by consensus or by 
consulting a third reviewer. We will assess for duplication 
of the data by comparing characteristics of the mother or 
baby and the settings of the studies. If required, we will 
contact the authors of primary studies for clarification 
about duplicate data. Where possible, we have planned 
a semiautomated process to identify duplicates and facili-
tate rapid update of search and data extraction.
Analysis
We will undertake narrative syntheses and perform aggre-
gate meta- analyses when there are at least two studies with 
minimal clinical heterogeneity. Dichotomous outcomes 
will be summarised as proportions, OR and continuous 
outcomes as standardised mean differences. We will use 
random effects model for the analysis when the number 
of studies permits to estimate between- study variance. To 
summarise proportions, we will use Freeman- Tukey trans-
formation to stabilise variances while dealing with studies 
with zero events. We will provide 95% CIs and predictive 
intervals (PI) to report on the precision of estimates and 
to aid the interpretation of heterogeneity. Heterogeneity 
will be reported as I2 and τ2 statistics.
Preplanned subgroup analysis will be by (a) suspected/
probable or confirmed COVID-19, (b) diagnosis in preg-
nancy or postnatal period, (c) trimester of diagnosis 
(first, second or third), (d) country income- level (high- 
income or low- income and middle- income country), 
(e) screening strategies (universal, symptom- based or 
Figure 1 Steps in the living systematic review (LSR) on 
COVID-19 in pregnant and postpartum women.
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risk- based testing), (f) maternal risk status (low or high) 
and (g) study quality (low or high). We will undertake 
additional sensitivity analysis to explore the effects of 
different populations (unselected, selected) and by 
excluding women with suspected COVID-19 and studies 
at high risk of bias. We will use trial sequential analysis 
to control for type I and II errors while accounting for 
updating estimations of between- study heterogeneity. A 
priori assumptions on statistical power, minimal clinically 
relevant effect and heterogeneity between trials will be 
used to define maximum sample size to detect such an 
effect. Boundaries of statistical significance according to 
sample size will be defined and used to determine statis-
tical significance for each systematic review update result.
Table 1 Study participants, risk factors and outcomes evaluated in the living systematic review on COVID-19 in pregnant and 
postpartum women
Population Pregnant/ postpartum/postabortal women with suspected or confirmed COVID-19 infection
Risk factors Maternal
Age, ethnicity, pre- existing medical conditions (including diabetes, chronic hypertension, asthma 
and Chronic Obstructive Pulmonary Disease), smoking, immunosuppression, gestational diabetes, 
symptoms, hypertensive disorders in pregnancy (pre- eclampsia, pregnancy- induced hypertension), 
body mass index ≥30, multiple pregnancy, in vitro fertilisation, parity, gestational age, mode of delivery, 
pregnancy status (pregnant or delivered), reproductive tract infections, symptoms and abnormal lab 
results.
Clinical manifestations Symptoms and signs
Cough, fever, breathlessness, sputum, myalgia, fatigue, diarrhoea, headache, sore throat, chest pain, 
rigour, ageusia, anosmia, nausea or vomiting, Sequential Organ Failure Assessment (SOFA), Quick 
SOFA, asymptomatic presentation
Laboratory
White cell count, lymphocyte count, haemoglobin, anaemia, platelet count, albumin, Alanine 
aminotransferase, Aspartate transaminase, C- reactive protein, creatinine, lactate dehydrogenase, 
creatine kinase, high- sensitivity cardiac troponin, prothrombin time, D- dimer, serum, ferritin, 
interleukin-6, procalcitonin
Radiological
Consolidation, ground- glass opacity, bilateral pulmonary infiltration, unilateral pulmonary infiltration, 
abnormal chest X- ray, abnormal chest CT
Outcomes Maternal COVID- related outcomes
Mortality: all- cause mortality, COVID- specific mortality
clinical respiratory syndrome: pneumonia, respiratory failure, acute respiratory distress syndrome, 
severe pneumonia; invasive ventilation, non- invasive ventilation, oxygenation; long- term respiratory 
outcomes
Time from illness onset to outcome (death, recovery)
Hospitalisation: admission to intensive care unit (ICU), admission to hospital, ICU length of stay
Organ failure: sepsis, septic shock, cardiac failure, coagulopathy, thromboembolism, acute cardiac 
injury, acute kidney injury, acute hepatic failure, cytokine storm syndrome (haemophagocytic 
lymphohistiocytosis), hypoproteinaemia, acidosis, central nervous system manifestations, secondary 
infection, duration of viral shedding
delirium, acute neuropsychiatric emergency, agitation, anxiety, depression, psychosis
Pregnancy- related outcomes
Preterm delivery (<37 w, spontaneous preterm delivery, induced preterm birth), preterm–premature 
rupture of membranes, prelabour rupture of membranes at (or near) term, miscarriage (spontaneous), 
induced abortion, mode of delivery, induction of labour, chorioamnionitis, wound infection, pregnancy- 
induced hypertension, gestational diabetes, antepartum haemorrhage, postpartum haemorrhage
Offspring outcomes
Stillbirth, neonatal death (early, late), foetal distress, foetal growth restriction postinfection, Apgar 
score at 1’, 5’; cord blood pH, gestational age at delivery, birth weight, large- for- gestational age, 
small- for- gestational age, congenital malformation, hypoxic ischaemic encephalopathy, neonatal 
seizures, neonatal infection (other than COVID-19), neonatal sepsis, neonatal asphyxia, disseminated 
intravascular coagulation, necrotising enterocolitis, respiratory distress syndrome, admission to the 
neonatal unit, length of stay in neonatal unit
Mother- to- child transmission outcomes
Evidence of virus in amniotic fluid, cord blood, placenta, placental membranes, vaginal fluid, breast 
milk, neonatal throat swabs, maternal and neonatal faeces and saliva samples; IgM antibodies in cord 
blood, neonatal blood
Duration of viral shedding after COVID-19 symptoms onset and after clinical resolution of signs/
symptoms in mother and in newborn
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We have established a pool of peer reviewers to rapidly 
assess the findings. The initial prepeer- reviewed findings 
will be published in a dedicated website, followed by the 
full findings when peer review is complete. We will simul-
taneously submit our work for publication in scientific 
journals with clear reference to the version of the living 
systematic review provided in that submission. Where 
journals allow, we will update our findings in the journals 
at set intervals required by the journal.
Patient and public involvement
Katie’s team patients and public involvement group—a 
dedicated women’s research and health advisory group 
were involved in the design of the protocol and will 
contribute to the interpretation and dissemination of the 
result.
DISCUSSION
Our living systematic review will address key research 
questions relevant to SARS- CoV-2 infection in pregnancy 
and postpartum period. Our review is based on a prospec-
tive protocol with plans to continuously update all review 
processes from search to publication at specific time 
points. The findings of the review will directly inform 
living guidelines and policies as new evidence emerge.
Our detailed literature search is a major strength of 
the review. In addition to the WHO COVID-19 database, 
our links with Cochrane Fertility and Gynaecology and 
EPPI Centre groups and additional searches for studies 
mapped by dedicated websites as well as blogs and social 
media networks means that the chance of missing rele-
vant studies is reduced. Through our networks with key 
collaborators in the WHO (maternal, neonatal, child 
and adolescent health) COVID-19 research group27 and 
relevant working groups, we will be able to access and 
include unpublished data. Our collaborative links with 
researchers in China provide access to Chinese language 
databases, so that these studies are not missed.
We have developed the protocol to ensure that all 
stages of the review are robust by adhering to recom-
mended methods for conduct and reporting of system-
atic reviews.28 By restricting case reports and series to the 
research question on mother- to- child transmission alone, 
we will not only ensure that relevant cases are not missed 
but also avoid biassed estimates for other research ques-
tions on risk factors and prevalence. Determination of 
mother- to- child SARS- CoV-2 transmission is particularly 
challenging since there is no consensus on what consti-
tutes intrauterine, intrapartum and postpartum transmis-
sion (including breast milk vs horizontal transmission).6 
To maximise data collection addressing this question, we 
will include case reports and case series for this part of 
the review. We will collect data on all types of samples to 
enable evaluation of varying definitions of the evidence 
required for confirmation of mother- to- child SARS- CoV-2 
transmission and timing.
Our work is subjected to some limitations. Our protocol 
has been developed based on our current knowledge of 
the COVID-19. As the pandemic unfolds, emerging new 
evidence may require changes in the protocol. The system-
atic review will be influenced by the characteristics of the 
individual studies, which may comprise heterogeneous 
populations, definitions of COVID-19, sampling frames, 
test strategies for diagnosis, definitions and reporting 
of outcomes. We have addressed these challenges by 
clearly defining the inclusion criteria and by exploring 
heterogeneity through sensitivity and subgroup analyses. 
The findings will be reported as 95% CI to communicate 
the uncertainty around the pooled estimates and PI to 
anticipate the variability in new study estimates. Given 
the urgency of the situation in the pandemic era, many 
studies are published as preprints, often followed by a full 
publication at a later date. The living systematic review 
needs to be responsive to any changes in data between 
the preprint to full publication stage. Furthermore, there 
is a risk of duplicate data, as individual studies may report 
the findings of the same mother–baby data that have 
been published elsewhere. We plan to exclude studies 
with suspected duplicate data and contact the authors of 
the primary studies for clarification. This review may be 
subjected to publication bias, since studies with perceived 
positive results may be published faster than those with 
perceived negative results. We will continuously review 
registries of RCTs to detect trials that should have reported 
results but that have not done so and will contact corre-
sponding authors to obtain results.
Many of the automated tools for living systematic 
review are mainly developed for reviews on RCTs and 
not for observational studies.29 Unlike traditional system-
atic reviews, living systematic reviews require substantial 
investment in time and human resources and resources 
to regularly update the findings. Sustained funding is 
required to maintain the same level of output over a 
longer period of time. This is particularly challenging, as 
the publication rate of studies on SARS- Cov-2 infection in 
pregnancy and postpartum is likely to increase exponen-
tially. To ensure that all relevant studies are identified in a 
timely manner, in addition to traditional searches, we will 
use our collaborations with other global efforts to map 
studies on COVID-19 and pregnancy and postpartum and 
automated alerts to identify new evidence when it gets 
published. Given the wide scope of this review, numerous 
reviewers will be involved, requiring clear operating 
procedures and pathways in place for workflow, training, 
monitoring and quality assessment. The necessity to 
swiftly publish the collated evidence needs to be balanced 
against publishing the findings after peer review. To be 
able to sustain the level of reviewer turn- around every 
2 weeks will be a challenge.
To date, apart from Cochrane, very few journals provide 
specific guidelines for publication of living systematic 
reviews and its subsequent update.30 Various models of 
publication have been considered.31 The first model is 
similar to the Cochrane reviews, where with each new 
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update (usually done in yearly intervals), there is a new 
publication with a new version and DOI in PubMed with 
linked updates between versions. This model can also 
take into account any changes in authors between the 
versions.32 However, in the current situation of rapidly 
evolving evidence, this is likely to result in numerous 
publications, even if reported on a monthly basis. In 
the second model, the introduction and methods of 
the main manuscript do not change, with only changes 
in the results section, which is written in such a way that 
most of the information is provided in tables and figures 
that are revised along with the abstract. The Discussion 
section of the newer version can incorporate a paragraph 
on the implications of new findings. The manuscript 
will be less resource intensive to prepare in the second 
model, but the original version should have been written 
in a generic manner to accommodate new information 
emerging in subsequent versions. In another model, the 
findings of subsequent updated analyses appear as new 
appendices, with no changes in the original abstract or 
manuscript. While this model requires less efforts from 
authors, editors and peer reviewers, it can mistakenly 
provide inaccurate old evidence if readers only access the 
abstract. Furthermore, this model makes it difficult to 
add or remove authors according to the changes in their 
contribution to subsequent versions.
In the midst of the current pandemic, much still remains 
unknown about how SARS- CoV-2 infection affects preg-
nant and postpartum women and their babies compared 
with reproductive aged non- pregnant women. It is essen-
tial that clinicians’ decisions to manage pregnant and 
postpartum women and their babies with COVID-19 are 
guided by the evidence. Our living systematic review is 
well suited to rapidly provide updated findings for trans-
lation into clinical practice. The flexibility of the living 
systematic review needs to be matched by a willingness of 
journal editors and guideline makers to provide a frame-
work that allows rapid dissemination of the new findings.
Ethics and dissemination
No ethical concerns. The findings will be disseminated 
through a designated website, publications, presentations 
in webinars and social media.
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